Bausch Health Companies Inc. (BHC)

Market Cap	2.24B -3.7%
Revenue (ttm)	10.27B +6.7%
Net Income	157.00M
EPS	0.42
Shares Out	370.56M
PE Ratio	14.38
Forward PE	1.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,330,601
Open	6.09
Previous Close	6.11
Day's Range	5.96 - 6.10
52-Week Range	4.25 - 8.69
Beta	0.38
Analysts	Hold
Price Target	8.33 (+37.91%)
Earnings Date	Feb 18, 2026

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Thomas Appio
• Employees: 20,300
• Stock Exchange: NYSE
• Ticker Symbol: BHC
• Website: https://www.bauschhealth.com

Analyst Summary

According to 3 analysts, the average rating for BHC stock is "Hold." The 12-month stock price target is $8.33, which is an increase of 37.91% from the latest price.

Price Target

$8.33

(37.91% upside)

Analyst Consensus: Hold